Abstract 5187
Background
The practice of oncology is challenging, especially when dealing with terminally ill patients and end of life. This is not without an emotional impact on oncologists, with potential negative effect on patient care and personal lives. We aimed to outline the main factors that makes of patients’ death an emotionally difficult experience, and to identify practical coping strategies.
Methods
An online survey was completed by 128 oncologists from three North African countries and France, on March-April 2019. All surveys were anonymous and confidential. The questionnaire included socio-demographic information, and sections about patients’ death and coping strategies.
Results
Most respondents were female (83.5%) and young oncologists (20-40 years-old), with less than 10 years professional experience (85.3%), but seeing more than 50 patients per week, and experiencing 0-2 deaths per month. They were mostly from Tunisia (n = 99), Morocco (n = 25), Algeria (n = 2) and France (n = 2). The majority was medical oncologists (57.9%), then radiation oncologists (29.4%). More than two-thirds of the oncologists reported that young age, long-term relationship and family denial towards the prognosis were the main factors making death or therapeutic failure announcement the most difficult. Unexpected evolution leading to death, and the non-access to more effective treatment in our countries had an emotional impact on 70% of the oncologists. A variety of coping strategies was identified: mainly peer support from colleagues and/or family and friends (53.5%), practicing hobbies (39.4%), seeking support in praying and faith (26.3%). Addictive behavior and/or medications were reported in 9.1%, significantly in single respondents (p 0.051). A majority (n = 83) reported a change in their character noticed by their families since the practice of oncology. The oncologists expressed becoming better able to set priorities (48%), more humble and human (61.4%) and motivated to improve their quality of health care (33.9%).
Conclusions
Dealing with patients’ death and confronting therapeutic failure have obviously an effect on oncologists’ personal life. We need to be aware of this issue, and to propose different coping strategies and interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract